1Department of Botany, Lahore College for Women University (LCWU), Lahore, Pakistan;
2Department of Basic Medical Sciences, Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan;
3Centre for Applied Molecular Biology, University of Punjab, Lahore, Pakistan;
4Department of Environmental Sciences, LCWU, Lahore, Pakistan;
5Department of Information Technology, University of Punjab, Lahore, Pakistan;
6Research Centre for Optimal Health, School of Life Sciences, College of Liberal Arts and Sciences, University of Westminster, London, UK;
7Department of Surgery, College of Medicine, King Saud University Riyadh, Saudi Arabia
8Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
Breast cancer, the most common malignancy in developed countries, involves 12% of 20–34-year-old females. Herbal treatments for breast cancer are growing popular due to adverse effects of conventional treatments. Network pharmacology, ethnobotany, and in vitro studies have described bioactive compounds found in plants grown in Pakistan’s Southern Punjab for treating breast cancer. A quantitative analysis for selection of five plants was performed. Plant samples were collected, dried, prepared, and mounted on herbarium sheets. Phytochemicals were evaluated for chemical absorption, distribution, metabolism, excretion, and toxicity properties and target using SwissTargetPrediction. Potential breast cancer targets were identified via GeneCards database and database of gene disease association (DisGeNET). Enrichment analysis and protein interactions were exercised via database for annotation, visualization, and integrated discovery (DAVID) and Cytoscape. A drug compounds–genes–disease network found key genes for treatment, validated by molecular docking. The top three docking complexes withstood 200-nanoseconds (ns) molecular dynamics simulations in GROningen MAchine for Chemical Simulations (GROMACS) 2020, showing average Coulombic short-range interaction energies of apigenin with androgen receptor (-30.64 kJ/mol), apigenin with estrogen receptor 1 (ESR1; -62.35 kJ/mol), and luteolin with epidermal growth factor receptor (EGFR; -95.99 kJ/mol). Cytotoxicity of five plant extracts was analyzed on HepG2 and MCF7 cell lines. Liquid chromatography–mass spectrometry was performed for the compounds that had best half-maximal inhibitory concentration (IC50) value. This research investigates the anti-breast cancer mechanisms of plant flavonoids at molecular level.
Key words: breast cancer, molecular dynamics, DAVID, ethnobotany, Southern Punjab
*Corresponding Authors: Zubaida Yousaf, Department of Botany, Lahore College for Women University, Lahore, Pakistan. Email: [email protected]; Anthony Booker, Research Centre for Optimal Health, School of Life Sciences, College of Liberal Arts and Sciences, University of Westminster, 115 New Cavendish Street, London WIW 6UW, UK. Email: [email protected]; Riaz Ullah, Department of Pharmacognosy, College for Pharmacy, King Saud University, Riyadh, Saudi Arabia; Email: [email protected]
Academic Editor: Ismail Eş, PhD, Institute of Biomedical Engineering, Old Road Campus Research Building, University of Oxford, Headington, Oxford OX3 7DQ, UK
Received: 27 July 2024; Accepted: 30 November 2024; Published: 1 October 2025
© 2025 Codon Publications
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/)
Breast carcinoma is a major global health concern that affects millions of women globally and is the primary cause of fatalities associated with cancer. Breast cancer accounts for 2–3% of all cancer diagnoses and 14% of annual cancer deaths worldwide. It is also the most frequently identified cancer and the main factor in women’s cancer-related mortality (Bray et al., 2018). It is estimated that around 83,000 incidents of breast cancer are recorded annually in Pakistan. Approximately 40,000 women suffer from the disease each year. It does seem that the number of deaths from breast cancer is declining, though. According to the American Cancer Society predictions, 530 men and 43,700 women would have lost their lives to breast cancer in 2023 (Giaquinto et al., 2022). In spite of structural diversity, anticancer drugs have adverse effects. These adverse effects are mainly due to the detrimental effects that spread to normal cells. Over 80% of the global population, particularly in underdeveloped nations like Pakistan, depends on traditional medicines to fulfill all their medical needs. As one of the most frequent and deadly type of cancer in the world, breast cancer requires ongoing research to find new treatment approaches, including preventative strategies. Because of their various pharmacological characteristics, such as their anti-inflammatory, antioxidant, and anti-cancer effects, research on natural compounds, especially medicinal plant flavonoids (MPFs), has become more important in this regard (Nurgali et al., 2022; Ullah et al., 2020). This paper uses an in vitro investigation against MCF-7 and HepG2 cell lines, in addition to pharmacological networking, to validate MPFs as possible agents for the management of breast cancer. Approximately 60% of the currently used anticancer drugs are obtained from natural sources. Secondary metabolites exhibit potential to treat cancer and are still used widely as a source of therapeutic and preventive anticancer drugs (Rayan et al., 2017). During the last 10 years, a lot of research has been done to discover novel treatments that can lessen the adverse effects of the existing drugs (Dagogo-Jack and Shaw, 2018). Flavonoids (polyphenolic compounds) are produced by plants as secondary bioactive metabolites. They are responsible for pigment, taste, and pharmacological activities of plants (Scarano et al., 2018). Flavonoids plants possess antioxidant potential and shield plants from abiotic stress. Hence, various studies have been conducted to determine their beneficial role in treating a variety of acute and chronic human ailments (Vrhovsek et al., 2004). Pharmacological networking entails a thorough examination of the complex relationships that exist between flavonoids and important biological targets related to the advancement of breast cancer. The goal of this approach is to identify the intricate molecular processes that underlie flavonoids’ anticancer properties. This may yield important information for the logical development of designed treatments (Naponelli et al., 2015). Concurrently, MCF-7 and HepG2 cell lines research conducted in vitro provides essential platforms for assessing the effectiveness of herbal flavonoids in cancer prevention. A thorough evaluation of the broad-spectrum action of these drugs is provided by MCF-7, which represents breast cancer cells, and HepG2, which represents hepatocellular carcinoma cells. This study aims to find particular herbal flavonoids with strong anticancer potential by utilizing pharmacological networking and in vitro experiments. As phytochemicals are increasingly being considered as additional or alternative cancer treatments, the ultimate goal is to support the development of focused and effective therapeutic approaches for breast cancer (Martinez-Perez et al., 2014). To test our hypothesis, ethnobotanical data from Southern Punjab were collected and five plants from family Amaranthaceae were selected for further quantitative validation. Phytochemicals of the selected plants were retrieved from published resources while their molecular targets and anticancer mechanisms of action linked to the flavonoid detection were studied using network pharmacology. Seven extracted flavonoids are polar in nature. The most suitable solvent for the extraction of flavonoids as per literature were searched. For further verification, plant ethyl acetate extract was tested in vitro against MCF-7 and HepG2 cell lines. The extracts showing the best results were subjected to liquid chromatography–mass spectrometry (LCMS) studies to verify the presence of retrieved flavonoids from in silico studies. Collectively, this research validates the discovery of bioactive compounds, specifically flavonoids, for the treatment of breast cancer and provides scientific validation for the traditional usage of plants in cancer treatment.
This multiregional study was carried out in different parts of the Southern Punjab, Pakistan. It was chosen as the study area because of its unique geographical location (Figure 1). The ethnobotanical investigation was performed in the following different regions of Southern Punjab: Layyah (area: 6,291 km2), Khanewal (area: 4,349 km2), Muzaffargarh (area: 8,435 km2), Vehari (area: 20 km2), Multan (area: 3,721 km2), Dera Ghazi Khan (area: 70 km2), Lodhran (area: 1,790 km2), Bahawalnagar (area: 8,878 km2), Rajanpur (area: 12,318 km2), Bahawalpur (area: 246 km2), and Rahim Yar Khan (area: 92.71 km2). In research regions, 990 persons of various ages were interviewed between 2019 and 2022. The criteria of selection of plant species was based upon the information we gathered from the respondents. First, all the plants were collected and quantitative analysis (use value [UV], informant consent factor [ICF], fidelity level [FL], and relative frequency citation (RFC) were applied. Plant species showing greater use value were selected for further analysis. Multiple visits were planned to cover all seasonal variations of the study areas.
Figure 1. Geographical location of Southern Punjab, Pakistan.
Ethical approval was sought from the Departmental Ethical Committee, LCWU, Lahore, Pakistan, while approval from local government was also sought for ethnobotanical data collection. The face-to-face interview method was used to acquire ethnobotanical data. This procedure was implemented due to low literacy rate in the study area. As a result, the same methodology was used to collect data for therapeutic herbs as previously reported (Ahmed et al., 2007). The standard technique was employed for the preservation of plant material. Proper pressing keeps the necessary plant parts visible for identification and keeps them from curling throughout the drying process. Herbarium specimens that have been carefully pressed are more functional and attractive to the eye. The procedure involves arranging the plant specimens on a pressing frame that has straps tightened around it after they have been arranged in folded newsprint sheets partitioned by cardboard sheets (Balick, 1996).
Medicinal plants collected during this study were examined using a variety of quantitative characteristics (UV, ICF, FL, and RFC) and sorted in alphabetical order. The collected ethnobotanical data include names of plants, family, life form, part used, and diseases cured. First, plants were dried by pressing between the layers of newspaper to remove its moisture at room temperature for 1–3 weeks, and then mounted on herbarium sheets. The Flora of Pakistan (http://www.efloras.org/index.aspx) was employed to confirm the nomenclature, while for identifying the correct botanical name, the International Plant Name Index (IPNI) (www.ipni.org) was utilized.
Quantitative analysis of ethnobotanical data (ICF, FL, UV, and RFC; Bennett and Prance, 2000; Tabuti et al., 2003) was computed as cited in the literature. ICF was examined to demonstrate the uniformity of the information for various disease categories. The calculation was as follows:
where “Nur” and “Nt” represent the number of total use reports for a particular ailment category, and accordingly the number of taxa used for a specific ailment category. This consensus result varies from 0 to 1.
Fidelity level predicts the preference of one species over another for curing a particular disease. Higher value suggests that a plant is more effective at treating a certain condition whereas lower FL values indicate that a plant is less effective at treating diseases. It was derived using the following equation:
where “Ip” is the number of informants providing information about the use of a certain species for a particular disease category, and “Iu” represents the number of respondents reporting using the plant for any condition category.
The use value of reported species was computed using the following formula
where “U” is the total number of use reports per species, and “n” represents the total number of informants surveyed for a given plant. UVs are high if there are more usage reports of a plant, indicating that the plant is significant, whereas they are close to zero if there are few use reports.
The RFC was calculated using the following equation:
This relation indicates the local prevalence of each species and is determined by dividing “FC,” the number of informants reporting the usage of species by the total number of informers contributing to the survey (N) without considering the use-categories.
Plants with higher UV values were chosen for further examination, while diseases with a higher ICF index were chosen for additional research.
We obtained information regarding the phytochemicals of the selected plants from published resources. The plant’s name was entered into several search engines, including KNApSAcK (http://www.knapsackfamily.com/), PubMed (https://pubmed.ncbi.nlm.nih.gov/), GoogleScholar (https://scholar.google.com/), Tropicos (https://www.tropicos.org/), etc., to find active components. The PubChem database (available at: https://pubchem.ncbi.nlm.nih.gov) was explored to find the molecular formula, molecular weight, simplified molecular-input line-entry system (SMILES), etc. Using these canonical SMILES, the pharmacokinetic properties of complete active chemical ingredients were determined.
The online admetSAR tool (http://lmmd.ecust.edu.cn/admetsar2) (Yang et al., 2019) was utilized to evaluate the ADMET parameters for each component (Li, 2001). The oral bioavailability (OB) evaluates the oral bioavailability of pharmacological compounds, while DL reveals whether a medication and a component are sufficiently comparable to be considered potential pharmaceuticals. Then, the active chemicals that fulfill drug-likeness (DL ≥ 0.18) and oral bioavailability (OB > 30) requirements were utilized for further screening (Li, 2001).
SwissTargetPrediction (http://www.swisstargetprediction.ch/) is a computational tool used to guess the protein targets of bioactive compounds, such as small molecules and natural products. It was used to determine the possible targets of certain active components by providing it with their canonical SMILES strings from PubChem. The species under consideration was Homosapiens, and the expected outcomes were obtained. The possible targets were selected from GeneCards (https://www.genecards.org/) and database of gene disease association (DisGeNET) (https://www.disgenet.org/) using “BreastCancer” as the search keyword (Zhang et al., 2020). Targets from both datasets were consolidated, and redundant gene entries were excluded to enhance the integrity of the subsequent analysis. Using UniProtKB, the target’s standard name was ascertained, with Homosapiens being the selected organism. A Venn diagram was created to show the mutual objectives of stability and drug for prevalent diseases and chemicals that were identified as potential study targets.
Gene Ontology (GO) function and pathway enrichment for breast cancer targets were examined using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/) (Huang et al., 2009). The output data with P < 5×10-2 were selected for further analysis, with smaller P values indicating greater enrichment. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of DAVID was used to identify biological pathways in the gene targets of breast cancer, and pathways with P ≤ 0.05 were analyzed further.
The breast cancer gene targets were analyzed for protein–protein interactions using the online search tool for the retrieval of interacting genes/proteins (STRING) program (version 11.5) (https://string-db.org/). The interactions were then visualized and analyzed using Cytoscape (version 3.9.1) (Bhagya, 2023).
Cytoscape (version 3.9.1) was employed to generate a network of bioactive chemicals, proteins, and pathways, and duplicate data were deleted. In this network, nodes symbolize bioactive compounds and target genes, while edges symbolize connections between the compounds and targets. The significance of a component, target, or pathway in the network was measured using the degree, a topological metric that was calculated using Cytoscape’s analysis tool. The CytoHubba plugin for Cytoscape was used to identify target genes in the network.
The Protein Data Bank (PDB) provided the PDB formatted protein crystal structures of the top six putative breast cancer core targets. The water and other small molecules from the protein crystal structure complexes were removed using PyMOLv 2.4 (Schrödinger, L.L.C) (Schrödinger and Delano, 2020) and saved in the PDB format. The three-dimensional (3D) configurations of selected phytomolecules were attained from the National Center for Biotechnology Information (NCBI) PubChem (Kim et al., 2021), an online database in Spatial Data File (SDF) format. Furthermore, energy minimization was performed using the Yet Another Scientific Artificial Reality Application (YASARA) software (Krieger et al., 2009), subsequent docking calculations, adding Gasteiger charges, using AutodockTools1.5.6 (Morris et al., 2009), the structures were translated to PDBQT format. Following the acquisition of protein PDB files, AutoDock Tools 1.5.6 was used to process them, combining nonpolar hydrogens and adding Gasteiger charges before converting them to the PDBQT format. AutoDock Vina software (Scripps Research Institute) (Eberhardt et al., 2021) was then used to simulate molecular docking between the target proteins and potential bioactive compounds to determine their binding affinity. The binding affinity was used as an evaluation criterion, with lower values indicating better docking.
Molecular dynamics (MD) simulations were carried out to evaluate the binding affinities of the top-performing compounds following docking. The GROningen MAchine for Chemical Simulations (GROMACS) 2020 software was used for these simulations, which lasted for 200 ns. The protein topology was generated using the CHARMM36 force field (Huang and Mckerell 2013). While using the CHARMM general force field (CGenFF) server (https://cgenff.umaryland.edu), for MD simulation, the necessary ligand topology and parameters were produced. All the systems were solvated using the TIP3P water model and then neutralized with the necessary amounts of Cl− and Na+. Subsequently, the steepest descent minimization technique was employed to minimize the energy of every system, with a maximum of 50,000 iterations and less than 10.0 kJ/mol of force. A LINear Constraint Solver (LINCS) holonomic constraints, a 2 femtosecond (fs) timestep, the number of atoms, volume, and temperature (NVT) ensemble with a leap frog integrator, and position constraints were applied to the receptor and ligand of both systems for 100 ps during heating (300 K). During the number of atoms, pressure, and temperature (NPT) equilibration phase, the NPT ensemble was employed for 100 ps at a temperature of 300 K with a 2 fs timestep. The structure’s coordinates were saved every 10 picosecond (ps) during an MD production run lasting 200 ns at a timestep of 2 fs, which came after all systems were optimized and energy minimized. The trajectories were used for different dynamics evaluations after a 200 ns MD simulation, including root mean square deviation (RMSD) of ligands relative to the backbone of proteins. The amount of H-bonds between the ligand and proteins was estimated over a 200-ns period. The Coulombic short range (Coul-SR) and Lennard Jones short range (LJ-SR) ligand–protein interaction energies were also calculated.
A method for determining end-state free energy using GROMACS MD trajectory data is MM-PBSA. The user can choose from several parameters when using gmx MMPBSA, comprising estimates of the binding free energy using different solvation models (PB, GB, or 3D-RISM), computational alanine scans, entropy adjustments, and stability calculations (Valdés-Tresanco et al., 2021).
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used for analysis, and the plant extracts’ cell viability was recorded. HepG2 and MCF-7 human cancer cell lines were employed. The cell lines were grown in 10% fetal bovine serum (FBS) RPMI-1640 medium. The cells were kept in a humidified environment with 5% CO2 at 37°C.
The assay targets the mitochondrion’s nicotinamide adenine dinucleotide (NAD) + hydrogen (H) (NADH) dehydrogenase pathway in living cells. During this colorimetric approach, yellow tetrazoliren crystals breakdown to generate purple formazan. Since MTT formazan is insoluble in water, it crystallizes in cells into pro-pie needle-shaped crystals. MCF7 and HepG2 cells were used. Primary human hepatocytes (HH) are considered as the most reliable model for xenobiotic metabolism and cytotoxicity studies. However, a number of issues, such as insufficient availability of fresh human liver, difficulties in isolation procedures, brief life span, individuals’ heterogeneity, and expensiveness of the method, can limit its use in in vitro screening processes (Madan et al., 2003). Hepatocellular carcinoma cell line HepG2, the immortalized liver-derived cell line, is the best alternative proposed thus far, because it has unlimited availability and phenotypic stability. They have close genotypic resemblance to the normal liver cells with distinct differentiation (Sassa et al., 1987). Thus, HepG2 cell line provides the ideal screening approach for cytotoxicity potential of new chemical entities at the lead generation phase.
MCF-7 and HepG2 cells were grown in RPM11640 media supplemented with 10% FBS, 100 mg/mL of streptomycin, and 100 units/mL of penicillin. Cell line subculturing was kept in an incubator at a temperature of 37°C and 5% CO. After repeated doses of 24 and 48 h, cultures were observed (Alley et al., 1998). For 24 h, cell culture was carried out in a 96-well plate at 37°C with varying concentrations of foetal bovine serum (FBS). Cells in the negative control received simple medium treatment. After removing the supernatant from each well, cells were twice cleaned with phosphate buffer saline (PBS). The MTT solution was then added to the cells. After 4 h of incubation, formazan crystals started to grow on the cells. The resulting formazan crystals were dissolved in 100 µL of dimethyl sulfoxide (DMSO), and a microplate reader (Bio-RAD680, USA) was used to detect the absorbance intensity at 570 nm. The experiment was set up in randomized complete block design (RCBD), and the proportion of viable cells was calculated in comparison to the cells that were left untreated (Shahraki et al., 2016).
The LCMS analysis was executed for the separation of bioactive compounds from the ethyl acetate and n-hexane extracts of Salsola spp. and Digera muricata. The mobile phase consisted of two solvents: (a) deionized water with 0.04% acetic acid, (b) acetonitrile. For the purpose of ion identification, a full total ion chromatogram (TIC) positive mode scan was acquired. All the samples were eluted within 24.3 min. The TIC scan summary for all extracts revealed a similar pattern of peaks eluted. Retention time is the amount of time a solute remains in the column or in the polar mobile phase and non-polar stationary phase. Because of their physiochemical characteristics, different components in the solution have different flow velocities (Farag et al., 2007).
Different field visits were conducted to collect voucher specimens. Following careful drying and identification, all of the voucher specimens were adhered to the herbarium sheets and then stored in Herbarium, LCWU. Ethnobotanical information about plants for all seasonal variations from 2019 to 2022 was covered. There were 990 individuals surveyed, and the sample size was determined in the same manner as stated previously (Kadam and Bhalero, 2010). Nearly all of respondents were natives (Figure 2), and were aged 30–40 years (27%) and 40–50 years (23%). Most of the respondents were males (55%) while rest were females (45%); only 2% respondents were illiterate.
Figure 2. Demographic profile of respondents.
This study reveals that 51% of the flora comprised herbs, followed by shrubs (28%), trees (15%), and weeds (6%) as shown in Figure 3. Herbs may predominate because bioactive compounds help them to adapt to their surroundings (Howard et al., 2012). Herbs are followed by shrubs, whose dominance may be attributed to their multifaceted environmental benefits, as shrubs improve air quality by absorbing dust and contaminants. Shrubs are dependable and easy to cultivate if grown in a suitable climate and good soil, and they prevent erosion, which reduces the amount of storm water runoff and harmful contaminants in waterways (Howard et al., 2012).
Figure 3. Life form of plant species.
Leaves, stems, roots, flowers, fruits, and other plant components are used to treat various ailments. However, according to the current study, leaves are the most prevalent plant portion utilized to treat various diseases, accounting for around 32% of the research area. Because of the ease with which leaves could be obtained and handled, they were widely used to cure a variety of diseases. The leaves are followed by the entire plant (26%), roots (18%), fruit (14%), flowers (9%), and stem (3%); also, most leaves were used to manufacture herbal remedies (Figure 4). Leaves are increasingly being used in the production of herbal remedies not only in Southern Punjab, but across the province (Santosh Kumar et al., 2015).
Figure 4. Plant parts traditionally used for treating diseases.
The ICF values ranged from 0.08 to 0.96 for 11 conditions, such as fever, flu, analgesics (pain), toothache, gastrointestinal, urinary, respiratory, muscle, skin, digestive, heart diseases, and tumors (Table 1). Tumors had the highest ICF of 0.96, indicating that it is more prevalent at the research site, indicating that people were more responsive about the practice of medicinal plants to treat this disease. Analgesics (0.08) and urinary diseases (0.05) had the lowest ICF. Lower ICF values suggest that people in this area know little about using plants to treat these diseases. Typically, types of plants native to a region dictate the efficiency of ICF for treating diseases (Rajakumar and Shiwanna, 2009). It was observed that natives were using plants (Abutilon indicum (L.) Sweet, A. javanica, Alhagi maurorum Medik, Artemisia vulgaris L., Calotropis procera (Aiton) W.T. Aiton , D. muricata, Fagonia indica Burm f., H. curassavicum, H. strigosum, S. baryosma, Salsola aphylla, S. kali, Tamarix a phylla (L.) H. Karst, and Thuja occidentalis L.) for the treatment of tumors.
Table 1. Informant consent factor (ICF) of the collected plant species.
| Disease categories | No. of use reports | No. of taxa used | ICF |
|---|---|---|---|
| Fever, cold | 410 | 4 | 0.49 |
| Cancer | 221 | 7 | 0.96 |
| Pain | 453 | 9 | 0.08 |
| Heart | 112 | 3 | 0.79 |
| Digestive | 294 | 2 | 0.70 |
| Skin | 1,383 | 20 | 0.18 |
| Muscle | 307 | 3 | 0.51 |
| Respiratory | 201 | 6 | 0.85 |
| Urinary | 97 | 4 | 0.50 |
| Gastrointestinal | 267 | 7 | 0.56 |
| Toothache | 107 | 3 | 0.92 |
In the present study, UV ranged from 0.37 to 0.090 (Supplementary Table S1). The maximum UV was noted for C. album (0.090). Many regions of Pakistan also utilized UV-rich plants. Future herbal drug development would emphasize on plant species with greater UV levels, improve the sustainability and preservation of plant resources, and follow pharmacological and phytochemical screening. While the minimum UV was reported for Flueggea leucopyrus Willd (0.37) and Sophora millus (Royle) Baker (0.37), the majority of respondents knew little to nothing about these plant species or their ethnobotanical applications. Less information about a given species in the study area was indicated by lower UV levels, despite the fact that it was not possible to correlate quantitative data within the region prior to the first quantitative ethnobotanical documentation in this area, notably in Southern Punjab. The value of RFC ranged from 0.1 to 0.86 (Supplementary Table S1). The highest value of RFC was discovered in C. album (0.86). The most prevalent plants at that location were those with the highest RFC, and the majority of individuals feel that they had therapeutic potential. While the lowest value of RFC was present in Capparis decidua Edgew. In the present study, FL extended from 10.0% to 75.8% (Supplementary Table S1). The higher the FL value, the more would be the usage of plant. Maximum FL was present in S. baryosma (75.8%), while minimum FL was observed in C. decidua (10.0%). Respondents utilized these herbs to treat illnesses and for other uses. Informants dealing with particular illnesses revealed importance of higher FL value (Islam et al., 2014).
After locating, filtering, and removing duplicates, approximately 494 active compounds of S. Kali, S. baryosma, D. muricata, C. album, and A. javanica were obtained through a published literature and two databases, ADMET analysis and drug likeliness and OB (DL ≥ 0.18 and OB ≥ 30). Through the results of ADMET analysis of these 494 compounds, 15 active compounds (Figure 5) were chosen as effective components (DL ≥ 0.18 and OB ≥ 30). The molecular structure of these peculiar compounds was established using PubChem.
Figure 5. Screened compounds with oral bioavailability, drug likeliness, and chemical structures.
The SwissTargetPrediction database was utilized to build the 700 potential targets from seven chemical components. The GeneCard (Stelzer et al., 2016) and DisGeNet (https://www.genecards.org/) databases were explored to find prospective breast cancer targets, yielding 15,447 and 184 potential breast cancer targets, respectively. Prospective mapping of these 700 active protein targets in breast cancer revealed 16 common targets, which were classified as prospective breast cancer targets (Figure 6).
Figure 6. Venn diagram showing common targets.
A PPI network was acquired by STRING to illustrate relationships between 16 common targets of breast cancer, as shown in Figure 7.
Figure 7. Protein–protein interaction (PPI) network of common genes.
Cytoscape was used to construct a network to investigate the relationship between potential targets and active compounds. Seven active ingredients and 16 putative target genes were utilized to create a compound network target (Figure 8).
Figure 8. Disease compound network target.
The core orange node of the network symbolizes the Amaranthaceae family whereas purple nodes represent plant components found in the Amaranthaceae family. The remaining yellow nodes, on the other hand, are the possible breast cancer targets. A molecular docking investigation was performed on each target. Research of the Target–Compound network found that while the identical target may intermingle with several active compounds, one vigorous component could have an impact on many targets. This reveals that the plants in the Amaranthaceae family have numerous targets and multi-component effects in the treatment of breast cancer.
Protein-protein interactions are crucial because they reveal the relationship between targets and are adaptable, flexible, and selectable. The CytoHubba plugin, which has roughly 12 topological analysis methodologies, was used to identify target genes, such as androgen receptor (AR), ESR1, EGFR, and Cytochrome P450 family 1 subfamily A member 1 (CYP1A1), with the highest degrees. These genes are represented by green nodes in the network (Figure 9).
Figure 9. Target PPI network analysis. Topological analysis found four green targets as key nodes (green nodes are target genes with higher degrees, and orange nodes are other potential targets).
Gene Ontology annotations and KEGG pathway analysis on 16 anti-breast cancer targets revealed the molecular mechanism of selected plants in the management of breast cancer. The GO analysis resulted in the identification of 61 biological processes (BP), including apoptotic process, estrogen biosynthetic process, steroid biosynthetic process, mammary gland alveolus development, intracellular steroid hormone receptor signaling pathway, etc. Thirteen cellular components (CC) (Figure 10), including macromolecular complex, cytoplasm, nucleus, intracellular membrane-bounded organelle, etc., and 35 molecular functions, including enzyme bind KEGG study (Figure 11) suggested 22 anti-breast cancer pathways.
Figure 10. Gene ontology term biological process (GOTERM_BP) and gene ontology term cellular component (GOTERM_CC) pathways showing richment factor.
Figure 11. Gene ontology term molecular function (GOTERM_MF) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway showing richment factor.
It was used to find possible targets for drugs that could reduce the risk of developing breast cancer. The docking study accurately anticipated the components and the target gene’s great binding affinity. Linking the target genes with the outcomes of KEGG analysis in the breast-cancer pathway led to the identification of four target genes for docking: AR (PDBID:2AMA) with the resolution of 1.90, EGFR (PDBID:1IVO) with the resolution of 3.30, ESR1 (PDBID:1UOM) with the resolution of 2.28, and CYP1A1 (PDBID:6UDL) with the resolution of 2. Molecular docking was performed using AutoDock tools, and RMSD was determined using docking pose distance calculation (DockRMSD) program. The docking results of these four genes are displayed in Table 2.
Table 2. Docking score of target genes.
| Genes | Affinity (kcal/mol) | RMSD (Å) |
|---|---|---|
| AR | –11.2 | 0.447 |
| EGFR | –9.8 | 1.09 |
| ESR1 | –11.3 | 1.33 |
| CYP1A1 | –11.9 | 1.72 |
Notes. AR: androgen receptor; EGFR: epidermal growth factor receptor; ESR1: estrogen receptor 1; CYP1A1: cytochrome P450 family 1 subfamily A member 1; RMSD: root mean square deviation.
The method of molecular docking was used to identify potential targets for substances that could decrease the probability of breast cancer. The strong binding affinity between the component and the target gene was correctly predicted by the docking analysis. Four target genes for docking were found by comparing the target genes with the results of KEGG analysis in the breast-cancer pathway: AR (PDBID:2AMA) with the resolution of 1.90 Å, EGFR (PDBID:1IVO) with the resolution of 3.30 Å, ESR1 (PDBID:1UOM) with the resolution of 2.28 Å, and CYP1A1 (PDBID:6UDL) with the resolution of 2.85 Å. AutoDock Tools was used for molecular docking, and RMSD was calculated from DOCKRMSD (Bell and Zhang, 2019). Compounds were docked with their respective targets as shown in the results of CytoHubba (Table 3).
Table 3. Docking score of screened compounds with their respective legends.
| Compounds | Gene target | Affinity (kcal/mol) |
|---|---|---|
| Apigenin | AR | –8.9 |
| ESR1 | –8.3 | |
| EGFR | –8.6 | |
| Luteolin | AR | –8.8 |
| ESR1 | –8.5 | |
| EGFR | –8.3 | |
| Ferulicacid | EGFR | –6.3 |
| CYP1A1 | –8.3 | |
| Chrysin | AR | –8.6 |
| ESR1 | –8.9 | |
| CYP1A1 | –10.7 | |
| N–trans–feruloyl–4–O–methyldopamine | EGFR | –7.8 |
| 5,7,2,3 Tetrahydroxyflavone | EGFR | –8.2 |
| ESR1 | –9.1 |
The top six phytochemicals predicted by CytoHubba were docked against genes AR, EGFR, ESR1, and CYP1A1. The affinity of docked phytochemicals with their respective genes are presented in Table 3. By using the BIOVIA Discovery Studio program (version 4.5), protein ligand complex interactions were determined, which primarily evaluated various interactions (hydrogen-, hydrophobic-, pi-alkali-bond, and so on). Docking structures are shown in Figure 12. Docking structure of apigenin with AR along with interacting residues are shown in Figures 12A–E.
Figure 12. (A) Docking structure of apigenin with AR along with interacting residues. (B) Docking structure of luteolin with AR along with interacting residues. (C) Docking structure of chrysin with CYP1A1 along with interacting residues. (D) Docking structure of 5,7,2,3 tetrahydroxyflavone with ESR1 along with interacting residues. (E) Docking structure of ferulic acid with CYP1A1 along with interacting residues.
As Autodock vina perform rigid docking, where the receptor (usually a protein) is kept static while the ligand (the molecule being docked) is allowed to move. This approach does not account for the flexibility of receptor, which can lead to an incomplete representation of molecular interactions. These protein–ligand interaction includes ionic interactions, hydrogen bonds, and van der Waals interactions. Although quantum mechanics (QM) offers the most accurate estimation of these interactions, QM methods are often too computationally expensive for docking. To accelerate the process, simpler potential energy functions, typically related to force fields or statistical potentials, are used. However, despite improvements in force fields and scoring functions, they still lack detailed polarization effects and accurate proton affinity estimation. Strong binding contacts were observed between major active compounds and targets, as validated by molecular docking. The top three combinations are thought to be important in treating breast cancer because they could be effective on the main targets. Our results are supported by our docking study, and we can suggest these complexes as a treatment approach for breast cancer. Moreover, docking results were confirmed using MD simulations.
Molecular dynamics simulations are used to comprehend binding dynamics between ligands and proteins. One of the most useful and often utilized computer programs for exploring biological macromolecules is MD simulation. This is very useful for comprehending the dynamic behavior of proteins at various time scales, such as fast internal motions, slow structural alterations, and protein folding processes. On the basis of the highest scores from docking results, MD simulations were performed on the following three complexes: apigenin-AR, apigenin-ESR1, and luteolin-EGFR.
GROMACS was used to simulate the MD of apigenin-AR, apigenin-ESR1, and luteolin-EGFR complexes with all atoms for 200 ns. RMSD, hydrogen bonding, and interaction energies, such as Columbic short-range (Coul-SR) and Lennard–Jones short-range (LJ-SR) were examined for the trajectories. The RMSD values demonstrated that the ligands had strong interactions with the proteins. RMSD values for all three ligands ranged between 0.1 and 0.38 (Figures 13B, 14B, and 15B). During the simulation period of 200 ns, these data suggest that ligands shifted somewhat from their initial positions. Similarly, ligands exhibited a high number of hydrogen bonds with protein structures throughout the same time. This also indicates that the ligands bind to their respective proteins more effectively. H-bonds stabilize protein–ligand complexes. H-bonds interaction exploration was carried out on MD trajectories to conclude the total number of H-bonds generated between protein–ligand complexes to comprehend the binding affinity of ligands to proteins. The apigenin-AR, apigenin-ESR1, and luteolin-EGFR complexes showed H-bonds between 0 and 4.1, 0 and 4, and 0 and 4, respectively. The outcomes revealed that throughout the simulations, the total number of H-bonds produced by all protein–ligand complexes remained stable, as shown in Figures 13C, 14C, and 15C. In addition to this analysis, the Coul-SR and LJ-SR interaction energies for MD trajectories were also estimated. Apigenin with AR (Figure 13A), apigenin with ESR1 (Figure 1A), and luteolin with EGFR (Figure 15A) were shown to have average Coul-SR interaction energies of –30.6433, –62.3507, and –95.9883 KJ/mol, respectively. The LJ-SR interaction energies were found to be –146.702, –120.451, and –127.218 KJ/mol. These findings demonstrated that the interaction between luteolin and EGFR is relatively stronger than that of the other two complexes. Complexes are shown in Figures 13D, 14D, and 15D.
Figure 13. Complex of apigenin with AR. (A) Time (ns) vs. interaction energies (KJ/mol) plot for the MD simulation of docking complex involving receptor AR and ligand apigenin. (B) Time (ns) vs. root mean square deviation plot for the MD simulation of docking complex involving receptor AR and ligand Apigenin. (C) Time (ns) vs. the number of hydrogen bonds plot for the MD simulation of docking complex involving receptor AR and ligand apigenin. (D) Movement of ligand during MD simulation. The position of ligand at 10 ns, 50 ns, 100 ns, 150 ns, and 200 ns is shown in green, cyan, magenta, yellow, and blue color, respectively.
Figure 14. Complex of apigenin with ESR1. (A) Time (ns) vs. interaction energies (KJ/mol) plot for the MD simulation of docking complex involving receptor ESR1 and ligand apigenin. (B) Time (ns) vs. root mean square deviation plot for the MD simulation of docking complex involving receptor ESR1 and ligand apigenin. (C) Time (ns) vs. the number of hydrogen bonds plot for the MD simulation of docking complex involving receptor ESR1 and ligand apigenin. (D) Movement of ligand during MD simulation. The position of ligand at 10 ns, 50 ns, 100 ns, 150 ns, and 200 ns is shown in green, cyan, magenta, yellow, and blue color, respectively.
Figure 15. Complex of luteolin with EGFR. (a) Time (ns) vs. interaction energies (KJ/mol) plot for the MD simulation of docking complex involving receptor EGFR and ligand luteolin. (b) Time (ns) vs. root mean square deviation plot for the MD simulation of docking complex involving receptor EGFR and ligand luteolin. (c) Time (ns) vs. the number of hydrogen bonds plot for the MD simulation of docking complex involving receptor EGFR and ligand luteolin. (d) Movement of ligand during MD simulation. The position of ligand at 10 ns, 50 ns, 100 ns, 150 ns, and 200 ns is shown in green, cyan, magenta, yellow, and blue color, respectively.
Using this method, the binding free energies of the complexes were determined, and thermodynamic parameters ΔG, ΔH, and –TΔS were calculated. Here, ΔG represents the Gibbs free energy change upon ligand binding, ΔH denotes the enthalpy of binding, and –TΔS corresponds to the entropic contribution, specifically the conformational entropy associated with ligand binding. The calculated value is the effective free energy when the entropic factor is eliminated, and this is typically adequate for comparing the relative binding free energies of related ligands. The apigenin_AR showed ΔG = –14.43 kcal/mol, apigenin_ESR1 showed ΔG = –13.85 kcal/mol, and luteolin_EGFR showed ΔG = –8.13 kcal/mol. Stability of the complex depends upon the value of ΔG. More negative the value of ΔG, more stable is the complex. Hence, apigenin_AR and apigenin_ESR1 are more stable, compared to the third complex luteolin_EGFR. TΔS values of all complexes were positive as shown in Figure 16. For apigenin_AR, ΔH = –25.65 and -TΔS = 11.22. apigenin_ESR1 showed ΔH = –28.12 with -TΔS = 14.27. luteolin_EGFR showed ΔH = –21.49, while this complex showed –TΔS = 13.36.
Figure 16. Binding energies of apigenin_AR, luteolin_EGFR, and apigenin_ESR1 complexes.
The anticancer activity of S. kali, S. baryosma, D. muricata, C. album, and A. javanica extracts was evaluated through MTT assay. Two breast cancer cell lines were used, that is, HepG2 and MCF-7. N-hexane and ethyl acetate extracts were used for the calculation of these selected plants (Table 4). The percentage of viable cells was negatively correlated with the concentration of plant extract. There was a decline in the cell viability of cancer cells with an increase in concentration of plant extracts. Half-maximal inhibitory concentration (IC50) of ethyl acetate extracts showed that D. muricata L. showed more cytotoxic activity against MCF-7 in ethyl acetate extract as compared to n-hexane extract, that is, 30 µg/mL. A study showed the IC50 value of 50 µg/mL against prostate cancer cell line using leaf extract of D. muricata. Ethyl acetate extracts of S. kali, S. baryosma, C. album, and A. javanica showed the IC50 values of 34.3 µg/mL, 40.1 µg/mL, 37 µg/mL, and <30 µg/ml, respectively, against MCF-7, while the IC50 values of these plants in N-hexane extract was 48.1 µg/mL, 54.4 µg/mL, 42 µg/mL, and 36 µg/mL. S. kali also proved to be more cytotoxic against MCF-7 cell line. Any substance with anticancer properties may do so by either destroying cancer cells or altering the genetic make-up of healthy cells (Asare et al., 2015). While in case of HepG2 cell line in ethyl acetate plants, extracts showed the IC50 values of 42 µg/mL (C. album), 39 µg/mL (A. javanica), 46 µg/mL (D. muricata), 51 µg/mL (S. baryosma), and 54 µg/mL (S. kali).
Table 4. Cytotoxicity assay of S. kali, S. baryosma, D. muricata, C. album, and A. javanica extracts against MCF-7 and HEPG-2.
| Plant name | Part used | Extract | IC50 value | |
|---|---|---|---|---|
| MCF-7 (µg/mL) | HEPG-2 (µg/mL) | |||
| Chenopodiumalbum | Whole plant | Ethyl acetate | 37.0±1.42 | 42.0±1.97 |
| N-Hexane | 42.0±1.44 | 45.0±1.81 | ||
| Aervajavanica | Whole plant | Ethyl acetate | < 30±2.2 | 39.0±3.1 |
| N-Hexane | 36.0±2.4 | 42.0±3.7 | ||
| Digeramuricata | Whole plant | Ethyl acetate | 30.0±1.56 | 46.0±1.18 |
| N-Hexane | 44.0±1.35 | 50.0±1.49 | ||
| Salsola baryosma | Whole plant | Ethyl acetate | 40.1±1.99 | 51.4±2.93 |
| N-Hexane | 54.4±1.81 | 56.3±1.21 | ||
| Salsola kali | Whole plant | Ethyl acetate | 34.3±1.49 | <40±1.18 |
| N-Hexane | 48.1±1.56 | 54.0±2.30 | ||
Liquid chromatography–mass spectrometry was performed for the isolation of compounds from ethyl acetate and n-hexane extracts of best anticancer plants among the five selected plants. All of the compounds’ mass spectra were determined by measuring their retention time and mass-to-charge ratio (m/z). D. muricata and S. Kali were subjected to LC-MS analysis for confirmation of flavonoids among the two extracts, i.e., ethyl acetate and N-hexane. Consistent with other findings, the LC-MS results showed that the extracts include a variety of phytocompounds, including fatty acids, alkaloids, terpenes, and flavonoids (Al-Dalahmeh et al., 2022). It was discovered that flavonoids account for a greater reaction to different diseases and damage than any other chemical. Traditional folk remedies for gastrointestinal, vascular, and respiratory conditions use flavonoids. Ethyl acetate extract of D. muricata (Figure 17) contains various compounds, such as phenol,2,6-dibromo-4-nitro, benzene,4-chloro-2-iodo-1-methyl, cyclopropane carboxyanilide,3’,4’-dichloro,1,1-dichloro-2,2,2-trifluoroethyl chlorodifluoromethyl ether, l-methionine, N-methoxycarbonyl-, dodecyl ester, didocosyl succinate, l-methionine, n-heptafluorobutyryl-, octadecyl ester, tetratriacontyl pentafluoropropionate, tetrapentaconytyl benzene, 1-hexacontanethiol, lupeol, and luteolinetc. While its n-hexane extract showed the presence of barban, benzamide, N-(-4-flurophenyl)-4-methyl, cyclopropane, carboxyanilide, 3,4-dicloro, L-tyrosine, N-(trifluoroacetyl)-, butyl ester, trifluoroacetate (ester), octadecanoic acid, and 1,2-ethanediyl ester (Figure 18) In case of S. Kali, its ethyl acetate extract (Figure 19) showed various compounds, such as beta-cadinene, 4-aminobenzoic acid, N,N-bis(pentafluoropropionyl)-, tert.-butyldimethylsilyl ester, ethyl 5,7-dichloro-4-hydroxyquinoline-3-carboxylate, L-methionine, acetamide, N-(4-bromophenyl)-2-bromo, fumaricacid, D-alanine, fumaricacid, silane, L-tyrosine, N,O-bis(2,6-diflurobenzyl)-, methyl ester, beta-alanine, N-(2,6-difluorobenzoyl)-octyl ester, L-valine, n-heptafluorobutyryl-, octadecyl ester, ergotaman-3’,6’,18-trione, 12-hydroxy-2’-(1methylethyl)5’-(2-methylpropyl)-(5’alpha), Tetratriacontylheptafluoro butyrate, aluminium palmitate or hen pentacontylbenzene, L-methionine, L-leucine, n-heptafluorobutyryl, octadceyl ester, etc. Its n-hexane extract showed sarcosine, N-(2-thienylcarbonyl)-, pentodecylester, 3-phenoxybenzyl alcohol picolinyl oxy dimethyl silyl ester, 2-acetamino-5-bromobenzoic acid, trichlormethiazide, hexan amide, N-ethyl-N-(3-methhylphenyl)-6-bromo, triphenylphosphine selenide, tricosanoic acid, 1-dotetracontanethiol, hen tetracontyl cyclohexane, luteolin, etc. (Figure 20).
Figure 17. Chromatogram of ethyl acetate extract of Digera muricata.
Figure 18. Chromatogram of n-hexane extract of Digera muricata.
Figure 19. Chromatogram of ethyl acetate extract of Salsola kali.
Figure 20. Chromatogram of n-hexane extract of Salsola kali.
Breast carcinoma is a frequent cancer in women and a primary cause of death globally (Darooei et al., 2017). Medicinal plants exhibit a wide range of pharmacological actions due to the presence of bioactive metabolites (Fagbemi et al., 2003). Ethnopharmacological research for cancer treatment is continuously performed globally. In this study, ethnobotanical data were acquired through interviews from selected sites in Southern Punjab (Pakistan). In all, 990 respondents were chosen to gather data about the customary uses of plants used in Southern Punjab. The objective of this study was to calculate the anticancer potential of various plant species by using various quantitative indices. Five plant species (S. kali, S. baryosma, D. muricata, C. album, and A. javanica) with high ICF, UV, and RFC as potential candidates for further analysis were identified using network pharmacology. The outcomes indicated that the active components of the selected plant species had the ability to target key proteins involved in breast cancer signaling pathways, but further research is needed to confirm their effects on functional alterations and treatment outcomes. The findings indicate that the active components of the chosen plants can target key proteins linked to a variety of biological processes and signaling pathways involved in breast cancer. However, the functional alterations in these factors and the profound effects of the treatment still need to be clarified in additional animal studies and human clinical trials.
The GeneCard and DisGeNet databases identified an overall of 15,447 and 184 possible targets for breast cancer, respectively. The SwissTargetPrediction database gathered an additional 700 potential targets from seven chemical compounds. By mapping the data from these databases and phytochemical targets, we were able to identify 16 common breast cancer genes. These genes were used to create a network of phytochemicals and gene targets using Cytoscape. Among these, the genes with the highest degree of values in CytoHubba were AR, ESR1, EGFR, and CYP1A. KEGG enrichment analysis was conducted and several signaling pathways were identified that play a part in the growth and advancement of the disease. Gene ontology analysis was also performed, which identified 61 biological processes related to breast cancer, including processes involving apoptosis, steroids, and estrogen synthesis and mammary gland development. Based on their PPI network and KEGG enrichment analysis, we selected the following four key target proteins that were closely related to breast cancer: AR, ESR1, EGFR, and CYP1A1. These proteins are linked to breast cancer in various ways. For example, AR expression is associated with increased survival in ER+/AR+ breast cancer, and ESR1, which comes in two forms, called ERα and ERβ, is most closely correlated with carcinogenesis, while lack of ERβ expression is linked to tumor progression (Caiazza et al., 2015). EGFR is overexpressed in around 50% of triple-negative breast sarcoma and inflammatory breast growth (Masuda et al., 2021), and CYP1A1 is suspected to be convoluted in breast cancer due to its part in the metabolism of certain compounds that may increase the danger of oxidative stress and cancer.
Several active ingredients that target these proteins, including apigenin, luteolin, ferulic acid, chrysin, and N-trans-feruloyl-4-O-methyldopamine were identified. These phytochemicals have demonstrated therapeutic effects and anticancer properties, particularly in breast cancer. Molecular docking studies were performed and found that the binding affinities of the docked complexes ranged from –6.3 to –10.7 kcal/mol, indicating stable binding.
We also conducted MD simulations on three top-scoring docked complexes for 200 ns. In this study, MD simulations were also conducted to comprehend the behavior of the final compounds. MD simulations are a powerful tool in drug innovation and proposal because they offer detailed insights into the behavior of molecules and their interactions at anatomic level (Liu et al., 2018). MD simulations are particularly useful for studying the dynamics of proteins, which play a central role in many biological processes and are often targeted by drugs. In drug discovery, MD simulations are used to identify potential drug candidates and to optimize their properties, such as binding affinity and specificity. They can also be used to study the mechanisms of drug action and to predict the potential adverse effects of drugs. For example, MD simulations can help researchers understand how a drug molecule interacts with its target protein, which can provide valuable information about how the drug is likely to behave in the body. In addition to their use in drug discovery, MD simulations can also be used to study the arrangement and functioning of proteins to calculate the stability of protein–ligand complexes, and to design new proteins with desired properties (Ashraf et al., 2022). Overall, MD simulations are an important instrument for understanding the behavior of molecules and their interactions, which is critical for the improvement of new drugs and therapies.
In our study, all three complexes, such as apigenin_AR, luteolin_EGFR, and apigenin_ESR1 showed considerably lower LJ-SR and Coul-SR interaction energies. This indicated the strong binding of ligands with the receptors. Furthermore, the RMSD values for all three ligands with reference to the backbone were in the range of 0.1–0.36 Å, indicating the small change in the ligands’ position, compared to their original docked position. Using the MM-PBSA method, the complexes’ binding free energies were determined, ranging from –8.13 kcal/mol to –13.85 kcal/mol.
Based on the MD simulation data, we can say that shortlisted ligands could be good therapeutic candidates to be used in the future treatment of breast cancer. Even though many compounds isolated from plants are tested thoroughly for their anticancer properties, it is becoming more widely accepted that the beneficial effects of plants are caused by an intricate interaction of a complex combination of compounds present in the whole plant (additive/synergistic, and/or antagonistic), rather than constituents in single agents alone (Karna et al., 2011). The anticancer activity of ethyl acetate and n-hexane extracts of S. kali, S. baryosma, D. muricata, C. album, and A. javanica was evaluated through MTT assay. Results showed that D. muricata and S. kali are more cytotoxic among selected plants. Ethyl acetate extract of D. muricata observed cytotoxic (30 µg/mL) against breast cancer MCF7 cell line. In order to resist apoptosis and escape controlled growth, cancer has developed a number of strategies. Therefore, utilizing entire cell extracts, which have multiple constituents with various potential intracellular targets, may be superior to employing a single isolated plant ingredient.
In LCMS, the extracted ion chromatogram, which was created by extracting each peak from TIC, revealed that each peak’s intensity varied at the same location. Each compound’s MS spectra were acquired by the individual data acquisition (IDA) technique. Since temperature affects the thickness of the mobile phase, it is crucial for all chromatography modes. Adropin liquid viscosity is a result of rising temperature. As a result, temperature has an impact on both chromatogram retention and solute partitioning (between mobile and stationary phases) (Milićević et al., 2010). The retention time increases with increasing ratio (k). As a result, retention of each metabolite, as well as total flow rate, is determined by column temperature. The ability of the solute to dissolve in the melted phase and adsorbed in the dense phase determines the solute’s dispersal between two phases (mobile and stationary). The proportion of solute absorption in the mobile phase to the ratio in the stationary phase is known as the distribution ratio. Luteolin and other flavonoids identified by LC-MS analysis are common flavonoids. As common flavonoids are found in a variety of medicinal plants, traditional Chinese medicine has utilized luteolin-rich plants to cure variety of illnesses (Su et al., 2003). Based on the results of LC-MS analysis data, the selected plants are greatly endorsed as potential anticancer therapeutics.
The outcomes of this study has paved the approach for new breast cancer targets, multi-target chemical regimes, and representations of treatment efficacy. Experimental validation of ethyl acetate extracts of all screened plants (Salsola kali L., Salsola baryosma (Schult.) Dandy, Digera muricata (L.) Mart, Chenopodiumalbum L., and Aerva javanica (Burm. f.) Juss. ex Schult) has demonstrated a significant growth inhibitory effect on MCF-7 and HEPG2 cancer cell lines. The network analysis results suggest that these plants contain flavonoids with numerous targets that may act on a variety of pathways connected to breast cancer. Furthermore, the genes AR, EGFR, ESR1, and CYP19A1 have been recognized as prospective and real therapeutic targets for the inhibition and decrement of breast cancer.
All authors contributed equally to this article.
The authors had no relevant financial interests to disclose.
The authors thanked the Ongoing Research Funding Program (ORF-2025-110) at King Saud University, Riyadh, Saudi Arabia, for financial support.
Ahmed, M., Khan, M.A., Zafar, M., and Sultana, S. 2007. Treatment of common ailments by plant-based remedies among the people of district Attock (Punjab) of Northern Pakistan. African Journal of Traditional, Complementary and Alternative Medicines 4(1): 112–120. 10.4314/ajtcam.v4i1.31201
Al-Dalahmeh, Y., Al-Bataineh, N., Al-Balawi, S.S., Lahham, J.N., Al-Momani, I.F., Al-Sheraideh, M.S., Mayyas, A.S., Abu Orabi, S.T., and Al-Qudah, M.A. 2022. LC-MS/MS screening, total phenolic, flavonoid and antioxidant contents of crude extracts from three Asclepiadaceae species growing in Jordan. Molecules 27(3): 859. 10.3390/molecules27030859
Alley, M.C., Scudiero, D.A., Monks, A., Hursey, M.L., Czerwinski, M.J., Fine, D.L., Abbott, B.J., Mayo, J.G., Shoemaker, R.H., and Boyd, M.R. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Research 48(3): 589–601.
Asare, G.A., Afriyie, D., Ngala, R.A., Abutiate, H., Doku, D., Mahmood, S.A., and Rahman, H. 2015. Antiproliferative activity of aqueous leaf extract of Annona muricata L. on the prostate, BPH-1 cells, and some target genes. Integrative Cancer Therapies 4(1): 65–74. 10.1177/1534735414550198
Ashraf, M.A., Sayed, S., Bello, M., Hussain, N., Chando, R.K., Alam, S., and Hasan, M.K. 2022. CDK4 as a phytochemical-based anticancer drug target. Informatics in Medicine Unlocked 28: 100826. 10.1016/j.imu.2021.100826
Balick, M.J. 1996. Transforming ethnobotany for the new millennium. Annals of the Missouri Botanical Garden 83(1): 58–66. 10.2307/2399968
Bell, E.W., and Zhang, Y. 2019. DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism. Journal of Cheminformatics. 11(40): 1–9. 10.1186/s13321-019-0362-7
Bennett, B.C., and Prance, G.T. 2000. Introduced plants in the indigenous pharmacopoeia of Northern South America. Economic Botany 54: 90–102. 10.1007/BF02866603
Bhagya, N. 2023. Network pharmacology based investigation on the mechanism of tetrandrine against breast cancer. Phytomedicine Plus 3(1): 100381. 10.1016/j.phyplu.2022.100381
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68(6): 394–424. 10.3322/caac.21492
Caiazza, F., Ryan, E.J., Doherty, G., Winter, D.C., and Sheahan, K. 2015. Estrogen receptors and their implications in colorectal carcinogenesis. Frontiers in Oncology 5: 19. 10.3389/fonc.2015.00019
Dagogo-Jack, I., and Shaw, A.T. 2018. Tumour heterogeneity and resistance to cancer therapies. Nature Reviews Clinical Oncology 15(2): 81–94. 10.1038/nrclinonc.2017.166
Darooei, M., Poornima, S., Salma, B.U., Iyer, G.R., Pujar, A.N., Annapurna, S., Shah, A., Maddali, S., and Hasan, Q. 2017. Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population. Tumor Biology 39(2): 1010428317694303. 10.1177/1010428317694303
Eberhardt, J., Santos-Martins, D., Tillack, A.F., and Forli, S. 2021. AutoDock Vina 1.2. 0: new docking methods, expanded force field, and python bindings. Journal of Chemical Information and Modeling 61(8): 3891–3898. 10.1021/acs.jcim.1c00203
Fagbemi, K.O., Olajuyigbe, O.O., and Coopoosamy, R. 2023. Biogenic synthesis, characterization, antibacterial and antioxidant activities of silver nanoparticles mediated from Tamarindus indica Linn fruit pulp extract. Journal of Herbmed Pharmacology 12(4): 459–468. 10.34172/jhp.2023.43430
Farag, M.A., Huhman, D.V., Lei, Z., and Sumner, L.W. 2007. Metabolic profiling and systematic identification of flavonoids and isoflavonoids in roots and cell suspension cultures of Medicago truncatula using HPLC–UV–ESI–MS and GC–MS. Phytochemistry 68(3): 342–354. 10.1016/j.phytochem.2006.10.023
Giaquinto, A.N., Sung, H., Miller, K.D., Kramer, J.L., Newman, L.A., Minihan, A., Jemal, A., and Siegel, R.L. Breast cancer statistics, 2022. CA: A Cancer Journal for Clinicians 72(6): 524–541. 10.3322/caac.21754
Howard, K.S., Eldridge, D.J., and Soliveres, S. 2012. Positive effects of shrubs on plant species diversity do not change along a gradient in grazing pressure in an arid shrubland. Basic and Applied Ecology 13(2): 159–168. 10.1016/j.baae.2012.02.008
Huang, J., and MacKerell, A.D. Jr. 2013. CHARMM 36 all-atom additive protein force field: validation based on comparison to NMR data. Journal of Computational Chemistry 34(25): 2135–2145. 10.1002/jcc.23354
Huang, D.W., Sherman, B.T., and Lempicki, R.A. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4(1): 44–57. 10.1038/nprot.2008.211
Islam, M.K., Saha, S., Mahmud, I., Mohamad, K., Awang, K., Uddin, S.J., Rahman, M.M., and Shilpi, J.A. 2014. An ethnobotanical study of medicinal plants used by tribal and native people of Madhupur forest area, Bangladesh. Journal of ethnopharmacology 151(2): 921–930. 10.1016/j.jep.2013.11.056
Kadam, P., and Bhalerao, S. 2010. Sample size calculation. International Journal of Ayurveda Research 1(1): 55. 10.4103/0974-7788.59946
Karna, P., Gundala, S.R., Gupta, M.V., Shamsi, S.A., Pace, R.D., Yates, C., Narayan, S., and Aneja, R. 2011. Polyphenol-rich sweet potato greens extract inhibits proliferation and induces apoptosis in prostate cancer cells in vitro and in vivo. Carcinogenesis 32(12): 1872–1880. 10.1093/carcin/bgr215
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B.A., Thiessen, P.A., Yu, B., and Zaslavsky, L. 2021. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Research 49(D1): D1388–D1395. 10.1093/nar/gkaa971
Krieger, E., Joo, K., Lee, J., Lee, J., Raman, S., Thompson, J., Tyka, M., Baker, D., and Karplus, K. 2009. Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: four approaches that performed well in CASP8. Proteins: Structure, Function, and Bioinformatics 77(S9): 114–122. 10.1002/prot.22570
Li, A.P. 2001. Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today 6(7): 357–366. 10.1016/S1359-6446(01)01712-3
Liu, C., Zoph, B., Neumann, M., Shlens, J., Hua, W., Li, L.J., Fei-Fei, L., Yuille, A., Huang, J., and Murphy, K. 2018. Progressive neural architecture search. In: Ferrari, V., Hebert, M., Sminchisescu, C., Weiss, Y. (eds). Proceedings of the European Conference on Computer Vision (ECCV) 2018. pp. 19–34. 10.1007/978-3-030-01246-5_2
Madan, A., Graham, R.A., Carroll, K.M., Mudra, D.R., Burton, L.A., Krueger, L.A., Downey, A.D. et al. 2003. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metabolism and Disposition. 31(4):421–31. 10.1124/dmd.31.4.421
Martinez-Perez, C., Ward, C., Cook, G., Mullen, P., McPhail, D., Harrison, D.J., and Langdon, S.P. 2014. Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer. Biochemical Society Transactions 42(4): 1017–1023. 10.1042/BST20140073
Masuda, K., Horinouchi, H., Tanaka, M., Higashiyama, R., Shinno, Y., Sato, J., Matsumoto, Y., Okuma, Y., Yoshida, T., Goto, Y., and Yamamoto, N. 2021. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Journal of Cancer Research and Clinical Oncology 147: 245–251. 10.1007/s00432-020-03329-0
Milićević, D., Jurić, V., Stefanović, S., Baltić, T., and Janković, S. 2010. Evaluation and validation of two chromatographic methods (HPLC-Fluorescence and LC–MS/MS) for the determination and confirmation of ochratoxin A in pig tissues. Archives of Environmental Contamination and Toxicology 58: 1074–1081. 10.1007/s00244-009-9436-2
Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., and Olson, AJ. 2009. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. Journal of Computational Chemistry 30(16): 2785–2791. 10.1002/jcc.21256
Naponelli, V., Modernelli, A., Bettuzzi, S., and Rizzi, F. 2015. Roles of autophagy induced by natural compounds in prostate cancer. BioMed Research International 2015(1): 121826. 10.1155/2015/121826
Nurgali, K., Rudd, J.A., Was, H., and Abalo R. 2022. Cancer therapy: the challenge of handling a double-edged sword. Frontiers in Pharmacology 13: 1007762. 10.3389/fphar.2022.1007762
Rajakumar, N., and Shivanna, M.B. 2009. Ethno-medicinal application of plants in the eastern region of Shimoga district, Karnataka, India. Journal of Ethnopharmacology 126(1): 64–73. 10.1016/j.jep.2009.08.010
Rayan, A., Raiyn, J., and Falah, M. 2017. Nature is the best source of anticancer drugs: indexing natural products for their anticancer bioactivity. PloS One 12(11): e0187925. 10.1371/journal.pone.0187925
Santosh Kumar, M., Ankit, S., Gautam, D.N., and Anil Kumar, S. 2015. Biodiversity and indigenous uses of medicinal plant in the Chandra Prabha wildlife sanctuary, Chandauli district, Uttar Pradesh. International Journal of Biodiversity 2015(1): 394307. 10.1155/2015/394307
Sassa, T., Richter, W.W., Uda, N., Suganuma, M., Suguri, H., Yoshizawa, S., Hitota, M., and Fujiki, H. 1989. Apparent “activation” of protein kinases by okadaic acid class tumor promoters. Biochemical and biophysical research communications. 159(3):939–44. 10.1016/0006-291X(89)92199-2
Scarano, A., Chieppa, M., and Santino, A. 2018. Looking at flavonoid biodiversity in horticultural crops: a colored mine with nutritional benefits. Plants 7(4): 98. 10.3390/plants7040098
Schrödinger, L., and DeLano, W. 2020. PyMOL Available at: http://www.pymol.org/pymol (accessed: July 7, 2024).
Shahraki, S., Khajavirad, A., Shafei, M.N., Mahmoudi, M., and Tabasi, N.S. 2016. Effect of total hydroalcholic extract of Nigella sativa and its n-hexane and ethyl acetate fractions on ACHN and GP-293 cell lines. Journal of Traditional and Complementary Medicine6(1): 89–96. 10.1016/j.jtcme.2014.11.018
Stelzer, G., Plaschkes, I., Oz-Levi, D., Alkelai, A., Olender, T., Zimmerman, S., Twik, M., Belinky, F., Fishilevich, S., Nudel, R., and Guan-Golan, Y. 2016. VarElect: the phenotype-based variation prioritizer of the GeneCards Suite. BMC Genomics17: 195–206. 10.1186/s12864-016-2722-2
Su, X.L., Lin, R.C., Wong, S.K., Tsui, S.K., and Kwan, S.Y. 2003. Identification and characterisation of the Chinese herb Langdu by LC-MS/MS analysis. Phytochemical Analysis: An International Journal of Plant Chemical and Biochemical Techniques14(1): 40–47. 10.1002/pca.685
Tabuti, J.R., Lye, K.A., and Dhillion, S.S. 2003. Traditional herbal drugs of Bulamogi, Uganda: plants, use and administration. Journal of Ethnopharmacology 88(1): 19–44. 10.1016/S0378-8741(03)00161-2
Ullah, A., Munir, S., Badshah, S.L., Khan, N., Ghani, L., Poulson, B.G., Emwas, A.H., and Jaremko, M. 2020. Important flavonoids and their role as a therapeutic agent. Molecules25(22): 5243. 10.3390/molecules25225243
Valdés-Tresanco, M.S., Valdés-Tresanco, M.E., Valiente, P.A., and Moreno, E. 2021. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. Journal of Chemical Theory and Computation17(10): 6281–6291. 10.1021/acs.jctc.1c00645
Vrhovsek, U., Rigo, A., Tonon, D., and Mattivi, F. 2004. Quantitation of polyphenols in different apple varieties. Journal of Agricultural and Food Chemistry 52(21): 6532–6538. 10.1021/jf049317z
Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., and Tang, Y. 2019. admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinformatics 35(6): 1067–1069. 10.1093/bioinformatics/bty707
Zhang, X., Shen, T., Zhou, X., Tang, X., Gao, R., Xu, L., Wang, L., Zhou, Z., Lin, J., and Hu, Y. 2020. Network pharmacology based virtual screening of active constituents of Prunella vulgaris L., and the molecular mechanism against breast cancer. Scientific Reports 10(1): 15730. 10.1038/s41598-020-72797-8
Table S1. Indigenous Plant-Based Remedies and Their Ethnobotanical Context from Southern Punjab.
| Sr. No. | Scientific name/local name | Family/voucher No. | Life form | Habitat | Part used | Method of preparation | Diseases cured | FL | UV | RFC |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Abrus precatorius Linn.Rati | PapilionaceaeLCWU-19-42 | Herb | Wild | Root and leaves | Extract | Tonic, removes biliousness; useful in eye diseases;cures leucoderma, itching, skin diseases,and wounds, stomatitics, asthma, and thirst | 30.43 | 0.57 | 0.34 |
| 2. | Abutilon indicumL.(Pattear) | MalvaceaeLCWU-19-9 | Shrub | Cultivated | Leaves | Decoction/infusion | Analgesic, to cure diarrhea, bleeding piles, and toothache | 40 | 0.73 | 0.4 |
| 3. | Acacia arabica L. wildbabool | MimosaceaeLCWU-15-3301 | Tree | Wild/cultivated | Bark, lLeaves, gum | Decoction | Bitter acrid; cures cough, bronchitis, diarrhea, burning sensation, and leucoderma, bronchitis, anti-dysenteric, and cures biliousness | 42.85 | 0.76 | 0.45 |
| 4. | Albizzia lebbek Linn.(Kala sirin) | MimosaceaeLCWU-15-3501 | Tree | Wild/cultivated | Bark, flower, seeds, pods | Decoction/powder/infusion | Restorative in piles, diarrhea, and dysentery, and skin diseases | 36.51 | 0.70 | 0.49 |
| 5. | Allium cepa(Wasal) | LiliaceaeLCWU-19-159 | Herb | Cultivated | Bulb | Infusion | Gastric problems, earache,urinary problems, and skin diseases | 40.83 | 0.5 | 0.6 |
| 6. | Allium sativam L.(Thoom) | LiliaceaeLCWU-19-150 | Herb | Wild/cultivated | Leaves, bulb | Infusion | Cardiac diseases, hysteria, flatulence, hypertension, leprosy, respiratory disease, eye disease, heart diseases, low fevers, inflammation, andpiles | 64.34 | 0.82 | 0.64 |
| 7. | Angelica glaucaChora | ApiaceaeLCWU-21-01 | Herb | Wild | Leaves | Decoction | Rheumatism, flatulence, and dyspepsia | 61.29 | 0.64 | 0.15 |
| 8. | Anisomeles indica Linn | LamiaceaeLCWU-21-02 | Herb | Wild/cultivated | Astringentand carminative | 33.67 | 0.60 | 0.49 | ||
| 9. | Azadirachta indica A JussNeem | MeliaceaeLCWU-15-53 | Tree | Cultivated/wild | Leaves, flowers, seed | Decoction | Chickenpox, ulcer, wounds, and snake bite | 57.14 | 0.72 | 0.49 |
| 10. | Bauhinia veriegata Linn.Kachnar | CaesalpiniaceaeLCWU-21-03 | Herb | Wild | Bark, root, buds | Infusion, paste | Liver, asthma, ulcers, piles, eye diseases, and dyspepsia | 52.84 | 0.80 | 0.61 |
| 11. | Berberis lyceum RoylKashmal | BerberidaceaeLCWU-21-04 | Shrub | Wild | Root, bark | Decoction | Tonic, intestinal astringent; good for cough, chest and throat troubles, piles and monorehagia, spleen troubles, and chronic diarrhea | 29.57 | 0.77 | 0.35 |
| 12. | Blepheris maderaspatensis L.Vachi vettu thalai | AcanthaceaeLCWU-19-135 | Herb | Wild | Leaves | Powder | Externally for cut and wounds | 40.84 | 0.54 | 0.35 |
| 13. | Boerhavia diffusa(Dakhari) | NyctaginaceaeLCWU-19-108 | Herb | Wild | Whole plant | Decoction/infusion | Anemia, as expectorant, and jaundice | 23.80 | 0.57 | 0.10 |
| 14. | Boerhavia procumbens(Dakhri /Satti) | NyctaginaceaeLCWU-19-110 | Herb | Wild | Root | Decoction | Amenorrhea and painful periods, cough, and asthma | 36.84 | 0.57 | 0.09 |
| 15. | Callicarpa macrophyllaDaya | VerbenaceaeLCWU-15-08 | Shrub | Cultivated/wild | Roots, leaves | Decoction | Disorders of stomach, and rheumatic joints | 39.24 | 0.58 | 0.39 |
| 16. | Calotropis giganteanWadha (Ak) | Asclepiadaceae LCWU-19-111 | Shrub | Cultivated | Whole plant, latex | Decoction/powder/infusion | Tonic, expectorant, anthelminthic, painful joints, scabies, ringworm of the scar, and purgative properties | 75 | 0.80 | 0.6 |
| 17. | Cannabis sativa Linn (Bhang) | CannabinaceaeLCWU-15-22 | Herb | Wild | Flower and leaves | Decoction | Analgesic, narcotic, anodyne, and antispasmodic | 37.27 | 0.63 | 0.55 |
| 18. | Capparis decidua(Karir) | CapparidaceaeLCWU-19-02 | Shrub | Wild | Whole plant | Decoction | Muscular injuries, ulcer, joint pain, rheumatic pains, asthma, and cough | 10 | 0.75 | 0.1 |
| 19. | Chenopodium albumBathu | AmaranthaceaeLCWU-15-04 | Herb | Cultivated | Leaves/stem (whole plant) | Decoction, paste, powder | Laxative, diuretic, cough, cooking, and breast cancer | 75.1 | 0.090 | 0.86 |
| 20. | Chrozophora tinctoria (Nilkhanti) | Euphorbiaceae | Herb | Wild | Whole plant | Decoction/powder/infusion | Emetic and cathartic | 22 | 0.58 | 0.25 |
| 21. | Citrullus colocynthis SchredTumba | CucurbitaceaeLCWU-19-33 | Herb | Wild | Fruit and roots | Decoction | Jaundice, urinary diseases, and rheumatism | 41.93 | 0.62 | 0.31 |
| 22. | Cloeome brachycarpaDhanar(khathoori) | CapparidaceaeLCWU-19-34 | Herb | Wild/cultivated | Whole plant | Decoction/powder/infusion | Painful joints and inflammation | 57.3 | 0.66 | 0.44 |
| 23. | Convolvulus arvensis(Naaro) | ConvolvulaceaeLCWU-15-23 | Weed | Cultivated | Whole plant | Powder | Chronic constipation | 64 | 0.76 | 0.5 |
| 24. | Convolvulus glomeratus [Choisy]Loaralli | ConvolvulaceaeLCWU-19-61 | Herb | Wild | Whole plant | Decoction/powder | Purgative | 37.14 | 0.42 | 0.35 |
| 25. | Coronopus didymus.(Charini boti) | BrassicaceaeLCWU-15-2003 | Weed | Wild | Whole plant | Decoction, paste | Laxative and diuretic | 35 | 0.62 | 0.2 |
| 26. | Crotalaria burhia(Chagg) | ResedaceaeLCWU-19-319 | Herb | Cultivated | Root | Infusion | General disorders | 70.4 | 0.70 | 0.35 |
| 27. | Curcuma domesticaL. (Halhard) | ZingiberaceaeLCWU-21-05 | Shrub | Wild | Rhizome | Powder | Body pain, and chickenpox | 43.33 | 0.65 | 0.3 |
| 28. | Cymbopogon jawaracusa(Bur/Khawi) | PoaceaeLCWU-19-140 | Herb | Wild | Leaves, flowers, roots | Infusion, decoction, paste | Joints pain, strengthening of gums, cough, chronic rheumatism, and leprosy | 73.07 | 0.80 | 0.65 |
| 29. | Cynodon dactylon(Khabbal) | PoaceaeLCWU-15-70 | Herb | Wild | Leaves, roots | Paste, infusion | Wound healing, chronic gleets, and bleeding piles | 42.85 | 0.68 | 0.35 |
| 30. | Datura innoxia Mill.(Batoora) | SolanaceaeLCWU-19-270 | Shrub | Cultivated/wild | Whole plant | Decoction/powder/infusion | Antipyretic, swelling of limbs, headache, toothache, and epilepsy | 35 | 0.81 | 0.3 |
| 31. | Digera muricataFalse Amaranth | AmaranthaceaeLCWU-21-29 | Herb | Cultivated | Whole plant | Powder | Digestive system disorders, urinary disorders, and cancer | 71.35 | 0.089 | 0.85 |
| 32. | Dodonaea viscose Linn.(Sanath) | SapindaceaeLCWU-21-06 | Shrub | Wild | Leaves and bark | Decoction | Fish poison, topical anti-rheumatic | 24.11 | 0.40 | 0.85 |
| 33. | Eclipta alba L.(Tikka) | AsteraceaeLCWU-15-13 | Herb | Wild | Leaves and root | Decoction | Prevent abortion, skin diseases, jaundice and fevers, and scalding of urine | 31.64 | 0.53 | 0.39 |
| 34. | Eucalyptus globulus (Sufaida) | MyrtaceaeLCWU-15-58 | Tree | Wild | Seed, leaves, oil | Decoction | Antiseptic, antibacterial, diuretic, cold, cough, for the remedies throat, lozenges, malaria, and toothache | 39.56 | 0.64 | 0.45 |
| 35. | Ficus racemosa(Gularoomul) | MoraceaeLCWU-19-272 | Herb | Wild/cultivated | Bark, fruit | Decoction | Carminative, and astringent | 39.50 | 0.60 | 0.40 |
| 36. | Ficus religeosa (Peppal) | MoraceaeLCWU-15-56 | Tree | Cultivated | Seed, fruit, bark | Decoction | Asthma, weakness of urinary bladder,and constipation | 21.64 | 0.40 | 0.48 |
| 37. | Flueggea leucopyrus (Wild karan) | EuphorbiaceaeLCWU-21-07 | Shrub | Wild | Leaves | Paste | Destroys worms in sores | 31.03 | 0.37 | 0.14 |
| 38. | Foeniculum capillacerm Mill. (Sunf) | ApiaceaeLCWU-19-195 | Herb | Wild | Seed, root, leaves | Decoction | Purgative, stomachic, anthelmintic, carminative, stimulant; cures intestinal troubles when applied to abdomen of children, diseases of the chest,spleen, headache, cough, and asthma; lesser inflammations; strengthens the eye, and venereal diseases | 18.18 | 0.81 | 0.60 |
| 39. | Frankenia pulverulenta Linn(Khareeya) | FrankeniaceaeLCWU-19-70 | Herb | Whole plant | Decoction | Mucilaginousand aromatic properties | 41.77 | 0.56 | 0.39 | |
| 40. | Fumarica indica(Shahtroo) | FumariaceaeLCWU-15-6202 | Herb | Wild | Whole plant | Decoction/powder/infusion | Chronic disorders, skin problems, antipyretic, blood purifier, and blood disorders | 30 | 0.87 | 0.35 |
| 41. | Gallium aparine Linn.(Banosha) | RubiaceaeLCWU-21-08 | Weed | Wild | Sape | Decoction | Diuretic | 45 | 0.49 | 0.6 |
| 42. | Geisekia pharnacoides Linn(Aluka) | FicoidaceaeLCWU-21-09 | Herb | Wild | Whole plant, leaves, stalks | Decoction/powder/infusion | Purgative and anthelmintic, scabies, heart troubles, and urinary diseases | 37.03 | 0.50 | 0.40 |
| 43. | Geranium ocellalum Canb.(Bhanda) | GeraniaceaeLCWU-21-10 | Herb | Wild/cultivated | Whole plant | Decoction/powder/infusion | Diuretic and astringent | 26.25 | 0.51 | 0.4 |
| 44. | Geranium rotunifolium Linn(Bhanda) | GeraniaceaeLCWU-21-11 | Herb | Wild | Roots | Decoction | Diuretic and astringent | 38.02 | 0.56 | 0.35 |
| 45. | Haloxylon recuvrum(Zeekhann/Kh ar) | ChenopodiaceaeLCWU-19-123 | Shrub | Wild | Whole plant | Decoction | Stomach disorders, and kidney stones | 48.5 | 0.57 | 0.17 |
| 46. | Heliotropium crispum (Karsan) | BoraginaceaeLCWU-19-125 | Herb | Wild | Whole plant | Infusion | Skin disorders | 24.3 | 0.78 | 0.20 |
| 47. | Heliotropium strigosum wild.(Gorakhpamo) | BoraginaceaeLCWU-21-12 | Herb | Wild | Whole plant | Juice, decoction | Laxative and diuretic, cure for stings of nettles and insects, and pain of limbs | 38.27 | 0.60 | 0.40 |
| 48. | Jasminum officinale(Chambely) | OleaceaeLCWU-21-13 | Shrub | Cultivated | Young shoots | Decoction | Oral candidacies, ringworm infection, and heart diseases | 58.27 | 0.71 | 0.69 |
| 49. | Kochia indica wt.(Bui) | ChenopodiaceaeLCWU-21-14 | Herb | Wild | Whole plant | Decoction/powder | Cardiac stimulant, and fever | 37.33 | 0.52 | 0.37 |
| 50. | Litsea monopetala(Maida lakri) | LauraceaeLCWU-21-15 | Tree | Wild | Bark | Decoction | Bone fractures, diarrhea, and astringent | 38.88 | 0.56 | 0.36 |
| 51. | Malvastrum coromendelianum(Jhar) | MalvaceaeLCWU-15-52 | Herb | Wild | Leaves and flowers | Decoction | Pectoral and diaphoretic, emollient, inflamed sores and wounds,and cooling and healing salve | 47.8 | 0.84 | 0.35 |
| 52. | Martynia annua L.(Hathjoy) | PedaliaceaeLCWU-21-16 | Shrub | Wild | Shoot and fruit | Decoction | Laxative, sorethroat, and epilepsy | 67.33 | 0.78 | 0.75 |
| 53. | Melia azedarach L.(Bakain) | MeliaceaeLCWU-15-5402 | Tree | Wild/cultivated | Young branches, leaves, and fruits | Decoction | Anthelmintic, and reheutism | 58.53 | 0.84 | 0.95 |
| 54. | Ocimum basilicum Linn (Naywee thulasi) | LamiaceaeLCWU-15-45 | Herb | Wild | Flower, leaves | Infusion | Reduces convulsions | 32.30 | 0.6 | 0.32 |
| 55. | Opuntia dillenii(Kunda thur) | CactaceaeLCWU-21-17 | Shrub | Wild | Leaves, fruit | Decoction | Stomachic, inflammations and pains, bronchitis, and tumors | 34.42 | 0.65 | 0.30 |
| 56. | Opuntia stricta Mill.(Thur) | CactaceaeLCWU-21-18 | Herb | Wild/cultivated | Fruit | Extract | Indolent ulcers | 34.69 | 0.42 | 0.24 |
| 57. | Oxalis corniculala Linn. Khatti mithi (booti) | OxalidaceaeLCWU-15-6101 | Weed | Wild | Whole plant (shoot) | Decoction | Scurvy | 54.30 | 0.74 | 0.93 |
| 58. | Phoenix acaulis(Pend) | PalmaceaeLCWU-21-19 | Date palm | Wild | Leaves | Decoction | Genitourinary diseases | 26.53 | 0.42 | 0.24 |
| 59. | Phoenix sylvestris(Pend) | PalmaceaeLCWU-21-20 | Tree | Wild | Root and fruit | Decoction | Spermatorrhoea, cardiac diseases, and anemic pregnant women | 22 | 0.4 | 0.25 |
| 60. | Polygonum plebeiumKheera (Wal) | PolygonaceaeLCWU-19-152 | Herb | Wild | Root and whole plant | Decoction and powder | Diarrhea, and pneumonia | 44.8 | 0.62 | 0.14 |
| 61. | Portulaca oleracea L.(Kulfa) | PortulaceaeLCWU-19-99 | Herb | Wild | Aerial part | Decoction/powder/infusion | Diuretic, and in Asthma | 48.10 | 0.62 | 0.39 |
| 62. | Portulaca tuberosa L. (Lunuk) | PortulaceaeLCWU-19-82 | Herb | Cultivated | Leaves | Infusion | Erysipelas and infusion in dysuria | 36.66 | 0.63 | 0.15 |
| 63. | Psidium guajava (Amrood) | MyrtaceaeLCWU-21-21 | Shrub | Wild/cultivated | Root, fruit | Decoction | Diarrhea, and skin disorders | 75.43 | 0.75 | 0.85 |
| 64. | Rhazya stricta DenceIshwarg | ApocynaceaeLCWU-19-84 | Shrub | Wild/cultivated | Leaves, fruit | Infusion, extract | Sore throat, and cooling medicine | 39.75 | 0.54 | 0.41 |
| 65. | Rosa alba Linn(Gulab) | RosaceaeLCWU-21-22 | Shrub | Cultivated | Flowers | Extract/decoction | Stomatitis, purifies the blood, improves the complexion, fevers, and palpitation of heart | 52.13 | 0.69 | 0.58 |
| 66. | Rosa gallica L.(Chota Gulab) | RosaceaeLCWU-21-23 | Shrub | Wild/cultivated | Petals | Extract/decoction | Slightly tonic and astringent, and useful in debility | 53.57 | 0.71 | 0.56 |
| 67. | S. baryosmaLoraan Lali | AmaranthaceaeLCWU-19-85 | Shrub | Wild | Leaves and whole plant | Powder | Cancer, hypertension, and washing clothes | 75.8 | 0.087 | 0.83 |
| 68. | Salsola aphylla(Ganna bush) | AmaranthaceaeLCWU-21-28 | Shrub | Wild | Leaves | Powder | Inflammation, pain relief, and early treatment of cancer | 71.1 | 0.086 | 0.82 |
| 69. | Salsola kali(Common saltwort) | AmaranthaceaeLCWU-19-86 | Shrub | Wild | Leaves | Decoction/powder | Influenza, losing weight, smallpox, boosts energy, boosts immune system, and in cancer | 73.5 | 0.078 | 0.81 |
| 70. | Salvadora oleoides(Peelu /jal, yellow-seeded) | SalvadoraceaeLCWU-19-28 | Shrub | Wild | Stem, root, oil, seed, leaves, bark | Decoction | Fever, menstrual period, cough, and rheumatism | 63.1 | 0.70 | 0.70 |
| 71. | Salvadora persica(Peelu, red-seeded) | SalvadoraceaeLCWU-19-29 | Tree | Wild/cultivated | Stem, root, oil, seed, leaves, and bark | Decoction | Fever, cough, rheumatism, and digestive disorders | 53.94 | 0.67 | 0.38 |
| 72. | Solanum nigrum Linn (Mako) | SolanaceaeLCWU-19-147 | Herb | Cultivated | Leaves, fruits, and leaves | Extract | Phthisis, jaundice, liver disease, diabetes, rheumatism, diarrhea, constipation, sore throat, skin disorders, and heart diseases | 53.84 | 0.80 | 0.45 |
| 73. | Sophora millis(RoyleLathia) | PapillionaceaeLCWU-21-24 | Herb | Wild | Whole plant | Decoction/powder | Tonic | 34.17 | 0.37 | 0.39 |
| 74. | Tamarindus indica Linn(Imali) | CaesalpiniaceaeLCWU-15-4301 | Tree | Wild/cultivated | Bark, leaves, and flowers | Decoction | Paralysis. gonorrhea, inflammatory swellings, eye diseases, and tumors | 46.92 | 0.7 | 0.65 |
| 75. | Tecomella undulate (Roxb.)Luar | BignoniaceaeLCWU-21-25 | Small tree | Wild | Bark | Decoction | Urinary discharges, leucoderma, syphilis, and cure for fever | 37.68 | 0.50 | 0.34 |
| 76. | Thevetia neriifolia(Pali kanar) | ApocynaceaeLCWU-19-07 | Shrub | Cultivated | Seeds | Oil | Urethral discharges, skin diseases, leucoderma and in piles, emetic, and purgative | 20 | 0.60 | 0.25 |
| 77. | Tribulus longipetalus(Bakhro bhust) | ZygophyllaceaeLCWU-19-158 | Herb | Wild | Fruit/whole plant | Decoction/powder/infusion | Painful urination, and spermatorrhoea | 39.5 | 0.58 | 0.43 |
| 78. | Tribulus terrestris linn.(Bakhro-bhust) | ZygophyllaceaeLCWU-19-013 | Herb | Wild | Leaves | Decoction/infusion | Diuretic, demulcent astringent, heart diseases, chest pain, and headache | 68.4 | 0.53 | 0.45 |
| 79. | Vernonia cinerea Linn.(Gandhavaki) | AcanthaceaeLCWU-21-26 | Herb | Wild/cultivated | Seeds, flowers | Decoction | Promotes perspiration, fevers,anthelmintic, and dropsy | 50.49 | 0.79 | 0.50 |
| 80. | Viola stacksii L.(Banafsha) | ViolaceaeLCWU-21-27 | Herb | Wild | Whole plant | Decoction/powder/infusion | Cold, cough, and fever | 52.72 | 0.74 | 0.27 |
Notes: Bolded diseases represent those for which the corresponding species is most frequently utilized in treatment.